AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by AMRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | ANDREW S BOYER | Executive Vice President | G | — | — |
| 2026-08-25 | ANDREW S BOYER | Executive Vice President | G | — | — |
| 2026-08-14 | John Kiely | Director | MIXED | — | — |
| 2026-08-13 | Nikita Shah | Executive Vice President | Sell | — | — |
| 2026-08-13 | J KEVIN BUCHI | Director | M | — | — |
| 2026-08-13 | Jason B. Daly | EVP, Chief Legal Officer | Sell | — | — |
| 2026-08-12 | Gautam Patel | Director | A | — | — |
| 2026-08-12 | Chintu Patel | Co-CEO | A | — | — |
| 2026-08-12 | Tushar Bhikhubhai Patel | 10%+ Owner | A | — | — |
| 2026-08-12 | Chirag K. Patel | President & Co-CEO | A | — | — |
| 2026-05-12 | Deborah M. Autor | Director | Sell | — | — |
| 2026-05-08 | PAUL M MEISTER | Director | M | — | — |
| 2026-05-08 | J KEVIN BUCHI | Director | M | — | — |
| 2026-05-08 | Gautam Patel | Director | M | — | — |
| 2026-05-08 | Ted C Nark | Director | M | — | — |
| 2026-05-08 | John Kiely | Director | M | — | — |
| 2026-05-08 | Deborah M. Autor | Director | M | — | — |
| 2026-05-08 | Shlomo Yanai | Director | M | — | — |
| 2026-05-08 | Jeffrey P. George | Director | M | — | — |
| 2026-03-27 | Chintu Patel | Co-CEO | A | — | — |
| 2026-03-27 | Chirag K. Patel | President & Co-CEO | A | — | — |
| 2026-03-05 | Jason B. Daly | EVP, Chief Legal Officer | MIXED | — | — |
| 2026-03-05 | ANDREW S BOYER | Executive Vice President | MIXED | — | — |
| 2026-03-05 | Chintu Patel | Co-CEO | MIXED | — | — |
| 2026-03-05 | Nikita Shah | Executive Vice President | MIXED | — | — |
| 2026-03-05 | Tasos Konidaris | Executive Vice President & CFO | MIXED | — | — |
| 2026-03-05 | Chirag K. Patel | President & Co-CEO | MIXED | — | — |
| 2026-03-03 | Chintu Patel | Co-CEO | A | — | — |
| 2026-03-03 | Jason B. Daly | EVP, Chief Legal Officer | A | — | — |
| 2026-03-03 | Chirag K. Patel | President & Co-CEO | A | — | — |
| 2026-03-03 | ANDREW S BOYER | Executive Vice President | A | — | — |
| 2026-03-03 | Tasos Konidaris | Executive Vice President & CFO | A | — | — |
| 2026-03-03 | Nikita Shah | Executive Vice President | A | — | — |
| 2025-11-19 | Ted C Nark | Director | Sell | — | — |
| 2025-11-14 | Nikita Shah | Executive Vice President | MIXED | — | — |
| 2025-08-28 | John Kiely | Director | Sell | — | — |
| 2025-08-25 | Nikita Shah | Executive Vice President | Sell | — | — |
| 2025-08-22 | ANDREW S BOYER | Executive Vice President | MIXED | — | — |
| 2025-08-15 | Tasos Konidaris | Executive Vice President & CFO | Sell | — | — |
| 2025-08-15 | Nikita Shah | Executive Vice President | Sell | — | — |
| 2025-08-13 | ANDREW S BOYER | Executive Vice President | Sell | — | — |
| 2025-08-13 | Nikita Shah | Executive Vice President | Sell | — | — |
| 2025-08-13 | Jason B. Daly | EVP, Chief Legal Officer | Sell | — | — |
| 2025-06-18 | Gautam Patel | Director | Sell | — | — |
| 2025-06-12 | Gautam Patel | Director | Sell | — | — |
| 2025-05-19 | Nikita Shah | Executive Vice President | Sell | — | — |
| 2025-05-13 | John Kiely | Director | Sell | — | — |
| 2025-05-08 | Jeffrey P. George | Director | M | — | — |
| 2025-05-08 | Emily Peterson Alva | Director | M | — | — |
| 2025-05-08 | J KEVIN BUCHI | Director | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 61,341,678 | — |
| — | — | 26,905,073 | — |
| — | President & Co-CEO | 22,662,890 | — |
| — | 10%+ Owner | 16,438,356 | — |
| — | — | 12,328,767 | — |
| — | Co-CEO | 7,770,255 | — |
| — | Director | 1,927,595 | — |
| — | Director | 832,800 | — |
| — | Director | 344,614 | — |
| — | Executive Vice President | 327,194 | — |
| — | Director | 325,848 | — |
| — | Director | 320,804 | — |
| — | Executive Vice President | 253,390 | — |
| — | Director | 211,029 | — |
| — | Director | 200,252 | — |
| — | Executive Vice President & CFO | 198,588 | — |
| — | Executive Vice President | 193,646 | — |
| — | Director | 168,576 | — |
| — | Director | 102,639 | — |
| — | President and CEO | 100,277 | — |
| — | Director | 93,660 | — |
| — | CFO | 82,986 | — |
| — | Director | 82,758 | — |
| — | SVP, Chief Scientific Officer | 37,500 | — |
| — | EVP, Chief Legal Officer | 35,171 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AMRX quote page; the site-wide leaderboard is on the insider transactions hub.